Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch
AV001
Phase 3 small_molecule active
Quick answer
Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch for Post-surgical neuropathic pain is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Post-surgical neuropathic pain
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active